Maxime Pichon1, Karine Lebail-Carval2, Geneviève Billaud3, Bruno Lina4, Pascal Gaucherand5, Yahia Mekki6. 1. University Hospital of Poitiers, Bacteriology and Infection Control Laboratory, Infectious Agents Department, 86021 Poitiers CEDEX, France. maxime.pichon@chu-poitiers.fr. 2. Hospices Civils de Lyon, Département de Chirurgie Gynécologique, Hôpital Femme-Mère-Enfant, 69000 Lyon-Bron, France. karine.le-bail-carval@chu-lyon.fr. 3. Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, 69317 Lyon CEDEX 04, France. genevieve.billaud@chu-lyon.fr. 4. Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, 69317 Lyon CEDEX 04, France. Bruno.lina@chu-lyon.fr. 5. Hospices Civils de Lyon, Département de Chirurgie Gynécologique, Hôpital Femme-Mère-Enfant, 69000 Lyon-Bron, France. pascal.gaucherand@chu-lyon.fr. 6. Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, 69317 Lyon CEDEX 04, France. Yahia.mekki@chu-lyon.fr.
Abstract
BACKGROUND: This three-step study evaluated ultraviolet-C (UV-C) efficacy against human papillomavirus (HPV) found on vaginal ultrasound probes. METHODS: The first two steps evaluated UV-C disinfection of vaginal ultrasound probes in routine condition. During the first phase, the probe (n = 100) was sampled after a complete cleaning and disinfection protocol, i.e., cleaning with chemically impregnated wipes, followed by UV-C. During the second phase, the probe (n = 47) was sampled after cleaning and UV-C. The final step consisted of applying mixes of HPV on a dedicated, covered probe (n = 15) then sampling the cover, the probe after removal of the cover, after cleaning, and after UV-C. HPV detection was performed using CLART® HPV2 PCR (Genomica, Madrid, Spain). RESULTS: In the first phase, no probes were found to be positive for both DNA after UV-C. In the second phase, eight probes were found to be positive after cleaning (seven with human DNA and one with HPV) and negative after UV-C. In the final phase, one probe was found to be positive for HPV for each sample except after UV-C. CONCLUSIONS: Covers followed by a chemically impregnated wipe are not sufficient to ensure patient safety during vaginal ultrasound examinations. UV-C is effective in routine conditions against contaminations found on vaginal ultrasound probes, especially HPV.
BACKGROUND: This three-step study evaluated ultraviolet-C (UV-C) efficacy against human papillomavirus (HPV) found on vaginal ultrasound probes. METHODS: The first two steps evaluated UV-C disinfection of vaginal ultrasound probes in routine condition. During the first phase, the probe (n = 100) was sampled after a complete cleaning and disinfection protocol, i.e., cleaning with chemically impregnated wipes, followed by UV-C. During the second phase, the probe (n = 47) was sampled after cleaning and UV-C. The final step consisted of applying mixes of HPV on a dedicated, covered probe (n = 15) then sampling the cover, the probe after removal of the cover, after cleaning, and after UV-C. HPV detection was performed using CLART® HPV2 PCR (Genomica, Madrid, Spain). RESULTS: In the first phase, no probes were found to be positive for both DNA after UV-C. In the second phase, eight probes were found to be positive after cleaning (seven with human DNA and one with HPV) and negative after UV-C. In the final phase, one probe was found to be positive for HPV for each sample except after UV-C. CONCLUSIONS: Covers followed by a chemically impregnated wipe are not sufficient to ensure patient safety during vaginal ultrasound examinations. UV-C is effective in routine conditions against contaminations found on vaginal ultrasound probes, especially HPV.
Authors: Luca Giannella; Giovanni Delli Carpini; Jacopo Di Giuseppe; Giorgio Bogani; Barbara Gardella; Ermelinda Monti; Carlo Antonio Liverani; Alessandro Ghelardi; Salvatore Insinga; Michele Montanari; Francesco Raspagliesi; Arsenio Spinillo; Paolo Vercellini; Elena Roncella; Andrea Ciavattini Journal: Infect Drug Resist Date: 2021-09-16 Impact factor: 4.003
Authors: C Kyriacou; E Robinson; J Barcroft; N Parker; M Tuomey; C Stalder; D Gould; M Al-Memar; T Bourne Journal: Ultrasound Obstet Gynecol Date: 2022-07 Impact factor: 8.678